4D Molecular Therapeutics, Inc. (FDMT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$12.36

From 52W high−27.33%

Volume401473.00

Market cap$672.81M

P/E (TTM)—

P/S (TTM)7.3x

Div yield—

Key dataNov 4, 2026

Open

$12.36

From 52W high

−27.33%

Volume

401473.00

Market cap

$672.81M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

P/E (TTM)

—

RSI (14)

44.6

MomentumView details →

1D Return

+1.91%

YTD Return

+57.27%

SummaryUpdated Jun 1, 2026

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage gene therapy company founded in 2013 and headquartered in Emeryville, California. The company went public in December 2020 and focuses on developing innovative gene therapies using proprietary adeno-associated virus (AAV) vectors to treat rare genetic diseases. Since its founding, 4D Molecular has built a pipeline of gene therapy candidates targeting diseases in ophthalmology, cardiology, and pulmonology, with multiple programs currently in clinical trials.

Ask drillr about 4D Molecular Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.9x

EV/Sales

3.8x

P/S (TTM)

7.3x

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

42.00%

Net Margin

−194.74%

EBITDA Margin

−199.94%

ROE (TTM)

−43.95%

ROA (TTM)

−36.37%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

—

EPS YoY

+22.95%

FCF YoY

+7.74%

Revenue CAGR 3Y

+200.86%

EPS CAGR 3Y

+18.79%

EBITDA YoY

+12.17%

MomentumView details →

1D Return

+1.91%

YTD Return

+57.27%

1Y Return

+12.23%

RSI (14)

44.6

vs 50D SMA

−12.49%

vs 200D SMA

+7.87%

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

8.03x

Quick Ratio

8.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.04

EPS Surprise

−1.96%

Beats (12Q)

4/12

Next Q EPS Est

−$1.06

Avg Surprise (4Q)

43.24%

Rev Surprise

4.45%

Financials snapshotView financials →

Revenue (TTM)

92.01M

Net Income (TTM)

−179.18M

Op. CF (TTM)

−156.07M

Next earningsNov 10, 2026 →

Latest newsMore news →

4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026 to present the clinical profile and commercial vision for its 4D-150 therapy.30d ago

4D Molecular Therapeutics enrolled the first patients across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME).37d ago

Similar companies

Aura Biosciences, Inc.AURA Geron CorporationGERN Candel Therapeutics, Inc.CADL Lexicon Pharmaceuticals, Inc.LXRX Design Therapeutics, Inc.DSGN Attovia Therapeutics, Inc.ATTO Find similar companies →

Latest newsMore news →

4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026 to present the clinical profile and commercial vision for its 4D-150 therapy.30d ago 4D Molecular Therapeutics enrolled the first patients across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME).37d ago 4D Molecular Therapeutics plans to initiate a Phase 3 trial for 4D-150 in diabetic macular edema in Q3 2026.82d ago